Announced Date: 2022-08-05 (August 18, 2025)
Asset Name: JMKX002992 (RG6537, GDC-2992)
Licensor: Shanghai Jemincare Pharmaceutical (China)
Licensee (Buyer): Genentech, member of Roche Group
.
Asset Modality: Small Molecule, oral degrader
Asset Target: Androgen receptor (AR) degrader
Potential Indication: prostate cancer
Current Stage:
.
Scope of Authority:
Jemincare will grant Genentech the exclusive license to develop and commercialize the degrader worldwide, and will be fully responsible for the development and commercialization costs.
.
Payment Detail:
Jemincare will receive：
Upfront payment of $60 million,
Regulatory and sales milestone payments up to $590 million.
Tiered royalties on net sales.
.
Link:
Jemincare Announces Exclusive License Agreement with Genentech to Develop and Commercialize Novel Oral Androgen Receptor Degrader
https://www.jemincare.com/news/detail.html?id=94
.
Note:
Chinese Name of Jemincare 济民可信
Chinese Name of Shanghai Jemincare Pharmaceutical 上海济煜
